



Radcliffe Observatory Quarter, Woodstock Road, Oxford. OX2 6GG

Tel: +44(0)1865 289300 • [qresearch@phc.ox.ac.uk](mailto:qresearch@phc.ox.ac.uk)

25<sup>th</sup> January 2023

Dr Defne Saatci  
University of Oxford

Dear Dr Saatci

Reference	OX94
Title	Development and validation of a risk assessment tool to improve early detection of childhood, adolescent and young adult cancer
Chief Investigator(s)	Dr Defne Saatci
Date Amendment requested	17.01.2023
Date Amendment approved	25.01.2023
Approval granted until	25.01.2024
Special conditions of approval	N/A

Thank you for submitting your amendment application to QResearch.

### Scientific Opinion

The members of the committee taking part in the review gave a favourable scientific opinion of the application for an amendment on the basis of the amendment application form and lay summary submitted to QResearch. The committee is satisfied that the research is appropriately designed in relation to its objectives and is likely to add something useful to existing knowledge in accordance with section 4.1.2 of the ethical conditions for QResearch. <https://www.qresearch.org/media/1155/257790-18em0400-qresearch-conditions-of-ethical-approval-27122018.pdf>

QResearch is a Research Ethics Approved Research Database and therefore this also constitutes research ethics approval. Please quote REC reference (18/EM/0400) in any publication arising from this work.

### Data Access

Subject to funding and relevant Data Sharing Agreements, the dataset requested will be provided to you.

### Approved documents

The documents reviewed were

Document	version	Date
Amendment Application Form		17.01.2023

The Nuffield Department of Primary Care Health Sciences is part of the NIHR School for

Primary Care Research. Head of Department: Professor Richard Hobbs FRCGP FRCP FESC FMedSci



**Reviewing Members of the Committee**

The members of the scientific committee who took part in the review are listed on the attached sheet.

**Annual Review and research outputs**

We will contact you annually for an update on progress with your research.

**Amendments and changes in responsibility**

Any changes to the protocol or responsibility of the applicants for the conduct of the research should be notified to [QResearch@phc.ox.ac.uk](mailto:QResearch@phc.ox.ac.uk)



Dr Paula Dhiman  
Chair of QResearch Scientific Committee

*Enclosures:*

*List of names and professions of members who took part in the review  
Amendment application form*

*Copy to: Prof Julia Hippisley-Cox, Chief Investigator of QResearch.*

**Reviewing Members of the Committee**

<b>Name</b>	<b>Profession</b>
Dr Paula Dhiman	Senior Researcher in Medical Statistics

## QResearch Application Amendment Form for Scientific Committee

### Project Information

1. **Project Reference Number:** OX94
2. **Project Title:** Development and validation of a risk assessment tool to improve early detection of childhood, adolescent and young adult cancer
3. **Chief Investigator:** Dr Defne Saatci

### Amendment Information

4. **Name of the person requesting the amendment:** Dr Defne Saatci
5. **Institutional email address of the person requesting the amendment:** [defne.saatci@phc.ox.ac.uk](mailto:defne.saatci@phc.ox.ac.uk)
6. **Date amendment requested:** 01/17/2021
7. **Amendment number:** 1
8. **Are there any changes to the exposures, comparators, or outcomes?:** We are planning to include additional exposures to this study, where our overall aim is to explore the early presenting features of childhood, teenage and young adult cancers. In the original approved version of the application the pre-diagnostic clinical features we listed only included demographics and symptoms/signs (via Read/SNOMED codes).  
We want to add specific blood tests (full blood count and inflammatory markers (CRP, ESR, ferritin LDH)) as exposures to quantify their association with a diagnosis of cancer in this age group. We want to add these exposures now as there is emerging evidence to suggest that routine blood tests taken prior to a diagnosis of a large group of cancers in adults could potentially aid earlier diagnosis and are correlated to diagnostic intervals<sup>1,2</sup>. It would be important to investigate if similar findings exist for childhood, teenage and young adult cancers and if so, addition of these markers to our risk prediction model may potentially improve model performance.
9. **References:** 1. Cranfield BM, Koo MM, Abel GA, Swann R, McPhail S, Rubin GP, Lyratzopoulos G. Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data. Br J Gen Pract. 2022 Sep 14:BJGP.2022.0265. doi: 10.3399/BJGP.2022.0265.  
2. Rafiq M, Abel G, Renzi C, Lyratzopoulos G. Inflammatory marker testing in primary care in the year before Hodgkin lymphoma diagnosis: a UK population-based case-control study in patients aged  $\leq 50$  years. Br J Gen Pract. 2022 Jul 28;72(721):e546-e555. doi: 10.3399/BJGP.2021.0617